Product Description
for Alcohol Dependence (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01613014)
Mechanisms of Action: V3 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: Eastern America
Company Founding Year: 1888
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Alcoholism|Depressive Disorder, Major|Binge Drinking
Phase 1: Depressive Disorder, Major|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01380704 |
M12-674 | P1 |
Completed |
Depressive Disorder, Major |
2011-09-01 |
2019-03-19 |
Treatments |
|
NCT01050127 |
M11-731 | P1 |
Completed |
Healthy Volunteers |
2010-02-01 |
2019-03-19 |
Treatments |
|
NCT01613014 |
NCIG-004 | P2 |
Completed |
Alcoholism|Binge Drinking |
2015-05-01 |
2019-03-19 |
Treatments |
|
NCT01741142 |
M11-733 | P2 |
Terminated |
Depressive Disorder, Major |
2013-10-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/03/2022 |
PubMed |
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. |
|
02/01/2022 |
PubMed |
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. |
|
07/14/2021 |
PubMed |
Vasopressin V1B Receptor Antagonists as Potential Antidepressants. |